RPRicardo Pérez-Rubio

Ricardo Pérez-Rubio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ricardo Pérez-Rubio has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interaction Between Glial Cells and Cerebellar Circuits in Epilepsy

    by Javier Pérez-Villavicencio, Ricardo Pérez-Rubio Flores, Héctor Romo-Parra, Carmen Rubio

    The cerebellum, long studied as the principal center for motor coordination, is now recognized as a participant in epileptogenic network dynamics through the pathway running from the cerebellar cortex to the deep cerebellar nuclei and on to thalamic and cortical targets. Purkinje cells are the sole inhibitory output of the cerebellar cortex, and Bergmann glia, a radial astrocyte population apposed to Purkinje cell dendrites and parallel-fiber synapses, sustain the perisynaptic environment on which Purkinje cell firing depends through glutamate clearance by GLAST/EAAT1, potassium buffering by Kir4.1, and calcium-dependent signaling. In cortex and hippocampus, loss of the equivalent functions in protoplasmic astrocytes lowers seizure threshold and produces spontaneous seizures, but no comparable experiment has been performed in Bergmann glia. Molecular genetics has identified numerous epilepsy-associated genes, of which only SLC1A3, KCNJ10 and AQP4 have cell-type-resolved expression in Bergmann glia; the remainder act on cerebellar circuits through neurons. In human epilepsy, cerebellar atrophy with Purkinje cell loss and Bergmann gliosis tracks cumulative seizure burden and antiseizure medication exposure rather than a primary cerebellar lesion and is therefore best read as reactive. Reactive astrogliosis is nonetheless accompanied by reduced glutamate transport and potassium buffering in sclerotic hippocampus, and whether cerebellar reactive gliosis carries the same homeostatic cost has not been measured. This review sets out the circuit-level, genetic and neuropathological evidence bearing on that question and specifies the experiments that would answer it.

  • Open Access

    Antiseizure Medications Impact Mitochondrial Ion Channels via Novel Bioenergetic and Neural Mechanisms

    by Carmen Rubio, Norma Serrano-Garcia, Ricardo Pérez-Rubio, Javier Pérez-Villavicencio, Héctor Romo-Parra, Ángel Lee, Moisés Rubio-Osornio

    Antiseizure medications (ASMs) have traditionally been characterized by their modulation of neuronal ion channels and synaptic processes; however, accumulating evidence indicates that numerous ASMs also directly modulate mitochondrial function. Specifically, several ASMs interact with ion channels located in both the inner and outer mitochondrial membranes, including the voltage-dependent anion channel (VDAC), the mitochondrial calcium uniporter (MCU), the mitochondrial Na+/Ca2+ exchanger (NCLX), the mitochondrial permeability transition pore (mPTP), and mitochondrial ATP-sensitive potassium channels (mitoKATP). Modulation of these channels regulates critical processes in epilepsy, including Ca2+ homeostasis, ATP synthesis, redox equilibrium, and susceptibility to neuronal apoptosis. Phenytoin and carbamazepine reduce voltage-dependent anion channel isoform 1 (VDAC1)-associated mitochondrial permeability by modulating the Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 protein (Bcl-2) ratio; ethosuximide limits mitochondrial Ca2+ overload through modulation of the MCU complex; valproic acid stabilizes NCLX function and prevents mPTP opening via antioxidant mechanisms; levetiracetam contributes to preserving intracellular Ca2+ handling; and mitoKATP activators, including diazoxide and retigabine, promote mitochondrial membrane potential stability and reduce seizure-induced reactive oxygen species (ROS) generation. The mitochondrial effects vary according to epilepsy subtype, contributing to the attenuation of hippocampal apoptosis in temporal lobe epilepsy and thalamocortical network modulation in generalized epilepsies. In this narrative review we examine the experimental and molecular evidence demonstrating how ASMs modulate mitochondrial ion channels and how these interactions contribute to their anticonvulsant mechanisms, thereby broadening the understanding of mitochondria as key functional components in antiseizure pharmacology.

  • Open Access

    Dysregulation of the Extracellular Matrix in the Synaptic Pathology of Parkinson’s Disease: Molecular Mechanisms and Novel Therapeutic Approaches

    by Carmen Rubio, Ricardo Pérez-Rubio, Javier Pérez-Villavicencio, Norma Serrano-García, Ángel Lee, Leticia Granados-Rojas, Martha Tena-Suck, Moisés Rubio-Osornio

    Parkinson’s disease (PD) is defined by the progressive degeneration of dopaminergic neurons within the substantia nigra and the pathological accumulation of α-synuclein (α-syn) aggregates. Beyond these intracellular hallmarks, the extracellular matrix (ECM) has emerged as an active regulator of synaptic dysfunction, neuroinflammation, and disease progression. Recent multi-omics evidence, including transcriptomic and proteomic profiling of post-mortem tissue and iPSC-derived neurons, demonstrates consistent dysregulation of ECM components across both sporadic and genetic PD subtypes—typified by downregulation of basement membrane collagens (COL4A) and integrin signaling (ITGB1), alongside upregulation of matrix metalloproteinases (MMPs). These alterations destabilize perineuronal nets (PNNs), allow prion-like α-syn propagation, and promote glial activation through TLR-mediated signaling. Circulating ECM-derived neoepitopes (C1M, C4M) may complement neurofilament light chain as prognostic biomarkers of disease progression, although prospective validation remains necessary. Pharmacological strategies targeting MMP activity (e.g., doxycycline), integrin–FAK signaling (ATN-161), and MMP–TIMP balance (mesenchymal stem cells) represent emerging therapeutic avenues, though clinical evidence in PD remains limited. This review synthesizes current evidence on ECM dysregulation in PD and discusses its implications for biomarker development and disease-modifying intervention.